Hookipa Cash Flow To Debt Ratio from 2010 to 2024

HOOK Stock  USD 2.15  0.15  6.52%   
Hookipa Pharma Cash Flow To Debt Ratio yearly trend continues to be quite stable with very little volatility. Cash Flow To Debt Ratio may rise above -19.81 this year. From the period between 2010 and 2024, Hookipa Pharma, Cash Flow To Debt Ratio regression line of its data series had sample variance of  38.18 and sample variance of  38.18. View All Fundamentals
 
Cash Flow To Debt Ratio  
First Reported
2010-12-31
Previous Quarter
(20.86)
Current Value
(19.81)
Quarterly Volatility
6.17927357
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Hookipa Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hookipa Pharma's main balance sheet or income statement drivers, such as Tax Provision of 454.6 K, Net Interest Income of 4.8 M or Interest Income of 5.2 M, as well as many indicators such as Price To Sales Ratio of 3.61, Dividend Yield of 0.0 or PTB Ratio of 0.81. Hookipa financial statements analysis is a perfect complement when working with Hookipa Pharma Valuation or Volatility modules.
  
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Latest Hookipa Pharma's Cash Flow To Debt Ratio Growth Pattern

Below is the plot of the Cash Flow To Debt Ratio of Hookipa Pharma over the last few years. It is Hookipa Pharma's Cash Flow To Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
Cash Flow To Debt Ratio10 Years Trend
Slightly volatile
   Cash Flow To Debt Ratio   
       Timeline  

Hookipa Cash Flow To Debt Ratio Regression Statistics

Arithmetic Mean(7.00)
Coefficient Of Variation(88.25)
Mean Deviation4.85
Median(3.19)
Standard Deviation6.18
Sample Variance38.18
Range17.6701
R-Value(0.77)
Mean Square Error16.69
R-Squared0.59
Significance0.0008
Slope(1.07)
Total Sum of Squares534.57

Hookipa Cash Flow To Debt Ratio History

2024 -19.81
2023 -20.86
2022 -4.77
2021 -13.17
2020 -8.67
2019 -8.84
2018 -3.41

About Hookipa Pharma Financial Statements

Hookipa Pharma investors utilize fundamental indicators, such as Cash Flow To Debt Ratio, to predict how Hookipa Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Flow To Debt Ratio(20.86)(19.81)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.